[go: up one dir, main page]

NO20075161L - Fremgangsmate for behandling av angstrelaterte lidelser - Google Patents

Fremgangsmate for behandling av angstrelaterte lidelser

Info

Publication number
NO20075161L
NO20075161L NO20075161A NO20075161A NO20075161L NO 20075161 L NO20075161 L NO 20075161L NO 20075161 A NO20075161 A NO 20075161A NO 20075161 A NO20075161 A NO 20075161A NO 20075161 L NO20075161 L NO 20075161L
Authority
NO
Norway
Prior art keywords
anxiety
procedure
treatment
related disorders
physiological
Prior art date
Application number
NO20075161A
Other languages
English (en)
Inventor
Sanjay Sabnani
Donald Wesson
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of NO20075161L publication Critical patent/NO20075161L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer og sykdom assosiert med indikasjoner forårsaket av en fysiologisk drivkraft til å lindre en følelse av angst.Etter én behandlingsmetode benyttes fremgangsmåter og blandinger for modulering av ekspresjonen av visse GABAA reseptor subenheter til å behandle angstrelaterte forstyrrelser og depressive forstyrrelser assosiert med fysiologisk toleranse overfor endogene neurosteroider.
NO20075161A 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser NO20075161L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72897905P 2005-10-21 2005-10-21
US72901305P 2005-10-21 2005-10-21
PCT/US2006/013152 WO2006110580A2 (en) 2005-04-07 2006-04-07 Methods for treating anxiety related disorders

Publications (1)

Publication Number Publication Date
NO20075161L true NO20075161L (no) 2008-01-07

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075161A NO20075161L (no) 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser
NO20075155A NO20075155L (no) 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20075155A NO20075155L (no) 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.

Country Status (12)

Country Link
US (3) US20080207601A1 (no)
EP (3) EP1868593A2 (no)
JP (3) JP2008538748A (no)
KR (2) KR20080004580A (no)
AU (3) AU2006235318A1 (no)
BR (2) BRPI0609744A2 (no)
CA (3) CA2604887A1 (no)
CR (2) CR9410A (no)
IL (2) IL186450A0 (no)
MX (2) MX2007012355A (no)
NO (2) NO20075161L (no)
WO (3) WO2006110642A2 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US8586634B2 (en) * 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
AU2010215075B2 (en) * 2009-02-20 2015-08-20 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20160120877A1 (en) * 2010-07-16 2016-05-05 James S Rowe Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
WO2013112605A2 (en) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
HUE056838T2 (hu) 2012-08-21 2022-04-28 Sage Therapeutics Inc Allopregnanolon makacs epileptikus állapot kezelésére
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
PT2935307T (pt) * 2012-12-18 2018-07-31 Univ Washington Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP4299126A3 (en) * 2014-06-26 2024-04-03 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
LT3565528T (lt) * 2017-01-09 2025-06-25 Relmada Therapeutics, Inc. Injekcinės suspensijos
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
EP3684347A4 (en) * 2017-09-18 2021-10-13 Sen-Jam Pharmaceutical LLC METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH OPIOID WITHDRAWAL
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
WO2019060171A1 (en) * 2017-09-20 2019-03-28 Calista Capital, Llc METHOD FOR STOPPING TOBACCO
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
WO2019193138A1 (en) * 2018-04-05 2019-10-10 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
CA3095682A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders
CA3113644A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
US11559502B2 (en) 2019-08-26 2023-01-24 Period Pill Bv Treatment of menstrual cycle-induced symptoms
US12233070B2 (en) 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
AU2021388076B2 (en) * 2020-11-27 2025-08-14 Trexapharm Pty Ltd Compositions comprising flumazenil and naltrexone and methods for use thereof
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
AU751496B2 (en) * 1997-08-28 2002-08-15 Vela Pharmaceuticals Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6403640B1 (en) * 1999-08-27 2002-06-11 Merck & Co., Inc. Method for treating chronic prostatitis or chronic pelvic pain syndrome
AU2002226427B2 (en) 2001-01-17 2006-11-16 Hythiam, Inc. Use of flumazenil in developing a drug for the treatment of alcohol dependence
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
JP4272885B2 (ja) 2001-02-15 2009-06-03 ハイチアム，インコーポレイテッド コカイン依存症治療用薬剤
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
JP5646126B2 (ja) * 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
EP1868593A2 (en) 2007-12-26
MX2007012355A (es) 2008-01-16
CA2603519A1 (en) 2006-10-19
US20080255097A1 (en) 2008-10-16
IL186450A0 (en) 2008-01-20
AU2006235257A1 (en) 2006-10-19
WO2006110642A3 (en) 2009-04-23
JP2008535852A (ja) 2008-09-04
NO20075155L (no) 2008-01-07
US8012958B2 (en) 2011-09-06
WO2006110557A3 (en) 2009-04-16
US20080280885A1 (en) 2008-11-13
BRPI0610693A2 (pt) 2016-11-22
EP1901727A4 (en) 2009-11-11
AU2006235234A1 (en) 2006-10-19
CA2604887A1 (en) 2006-10-19
EP1868432A4 (en) 2009-11-04
MX2007012353A (es) 2008-01-16
WO2006110580A2 (en) 2006-10-19
JP2008535850A (ja) 2008-09-04
EP1868432A2 (en) 2007-12-26
EP1901727A2 (en) 2008-03-26
WO2006110642A2 (en) 2006-10-19
WO2006110580A3 (en) 2007-08-16
KR20080004580A (ko) 2008-01-09
CA2603533A1 (en) 2006-10-19
BRPI0609744A2 (pt) 2010-04-27
JP2008538748A (ja) 2008-11-06
AU2006235318A1 (en) 2006-10-19
KR20080004581A (ko) 2008-01-09
WO2006110557A2 (en) 2006-10-19
CR9410A (es) 2008-02-21
US20080207601A1 (en) 2008-08-28
CR9413A (es) 2008-01-21
IL186447A0 (en) 2008-08-07
AU2006235257B2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
NO20075161L (no) Fremgangsmate for behandling av angstrelaterte lidelser
MX2011006224A (es) Composicion que comprende isoflavonas.
CR9867A (es) Anticuerpos humanos contra il13 y usos terapeuticos
ECSP088338A (es) Terapia de combinación de oxazolidinonas sustituidas para la profilaxis y el tratamiento de alteraciones del flujo sanguíneo cerebral
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
NI201100099A (es) Nuevos compuestos 578.
CO6781485A2 (es) Compuestos y su uso como inhibidores de bace
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
SG196775A1 (en) Chromenone analogs as sirtuin modulators
NO20090156L (no) Humanisert antistoff
CR9994A (es) Vacuna terapéutica
EP1482959A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
EP2286837A3 (en) Treatment of obesity and obesity related diseases
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
MY147217A (en) Antibody molecules having specificity for human il-06
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
MX2009011930A (es) Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
MX2011004870A (es) Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
GT200800167A (es) Inhibidores de pai-1 para tratamiento de afecciones musculares
WO2007055743A3 (en) Treatment of obesity and related disorders
TW200724147A (en) Cognitive abilities improving agent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application